Eurofins DiscoverX published a new Obesity Products Solutions Guide covering GLP-1 for deeper pharmacology insights and streamlined development workflows.
Published
Signal category
Research & Knowledge
Quote
“Review the new solutions guide to see how Eurofins DiscoverX can help accelerate next-generation obesity therapeutic development.”
— Eurofins DiscoverX team
Company
Eurofins DiscoverX
Eurofins DiscoverX® is the trusted drug discovery & development product solutions provider of Eurofins Discovery.
- Industry
- Biotechnology Research
- Location
- Fremont, US
- Company size
- 120 employees
Eurofins DiscoverX, the products company of Eurofins Discovery, is committed to enabling and accelerating multi-modality drug discovery and development from discovery to QC lot release. For drug discovery and development scientists, Eurofins DiscoverX is the trusted product solutions provider that accelerates research and drug discovery programs with confidence for cytokine receptors, checkpoint receptors, GPCRs, kinases, ion channels, epigenetics, nuclear receptors, and other target families. Eurofins DiscoverX develops and manufactures cutting edge assays, stable cell lines, ready-to-use kits (including bioassays), membrane preps, enzymes, and reagents for small molecule and biologic immuno-oncology, cytotoxicity, compound-target engagement, potency and QC lot release, pharmacotrafficking, and many other applications. These products are developed from 3 R&D and manufacturing centers of excellence – San Francisco Bay Area California (Fremont); St. Louis area, Missouri (St. Charles); and Poitiers, France.
Founded 2000